Bringing Nanoscience to Life

unimportant decoration Nano-scale droplet illustration

BlueWillow News

unimportant decoration

BlueWillow Biologics® Appoints Donald Cumming to Vice President of Marketing & Sales

ANN ARBOR, MI., August 11, 2020 – BlueWillow Biologics® (BlueWillow) a clinical-stage, privately-held biopharmaceutical company announced today that it has appointed Donald (Don) Cumming as Vice President of Marketing and Sales as of July 27, 2020.   

In this newly-created role, Cumming will have responsibility for marketing and sales operations for the company’s pharmaceutical brands including the launch of their new brand and innovation, NanoBio® Protect, the only alcohol-free, long-lasting nasal antiseptic, into the retail and eCommerce channels.

Cumming is a marketing professional with 15 years of progressive, multi-industry experience; most recently, he served as Global Marketing Director at Ranir LLC, a Perrigo company, where he oversaw marketing strategy and execution across a range of businesses that included cosmetic, OTC, and medical device category products.

“Cumming’s extensive marketing and sales acumen across a range of related businesses positions him well to enhance the market presence of BlueWillow’s brands and products,” said Chad Costley, President and Chief Medical Officer of BlueWillow Biologics.

Prior to Ranir, Cumming held a series of roles with increasing responsibilities with industry leaders from both retail and manufacturing sectors including 3M, Kellogg Co., and Meijer, where he held both brand and product development responsibilities. 

Cumming earned his Bachelor of Science degree in Industrial and Operations Engineering from the University of Michigan (Ann Arbor) and completed a dual Master’s degree program at Northwestern’s Kellogg School of Management where he earned his Master of Engineering Management (MEM) and his Master of Business Administration (MBA) degrees, majoring in Marketing and Strategy. 

About BlueWillow Biologics

BlueWillow Biologics® is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform. The platform employs novel oil-in-water nano-droplets for products administered to the skin and nose.

In addition to NanoBio® Protect, BlueWillow is currently developing intranasal vaccines that elicit both systemic and mucosal immunity for several respiratory and sexually transmitted infections, including Sars-CoV-2 (Covid-19), RSV, HSV2, pandemic influenza, and anthrax, as well as intranasal immunotherapy for peanut allergy and other allergic conditions. Visit www.BlueWillow.com for details on the company’s pipeline and studies completed to date.